Geron Corp
NASDAQ:GERN
Geron Corp
NASDAQ:GERN
Price:
3.87 USD
3.75%
Market Closed
Updated:
May 8, 2024
Geron Corp
Operating Income
|
Geron Corp
Operating Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Geron Corp
NASDAQ:GERN
|
Operating Income
-$210m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-19%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is Geron Corp's Operating Income?
Operating Income
-210m
USD
-210m
USD
Based on the financial report for Mar 31, 2024, Geron Corp's Operating Income amounts to -210m USD.
What is Geron Corp's Operating Income growth rate?
Operating Income CAGR 10Y
-19%
-19%
Over the last year, the Operating Income growth was -40%. The average annual Operating Income growth rates for Geron Corp have been -33% over the past three years , -44% over the past five years , and -19% over the past ten years .
You don't have any saved screeners yet
